Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Identifieur interne : 000072 ( PubMed/Curation ); précédent : 000071; suivant : 000073Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Auteurs : O R Obiako ; H M Murktar ; D. OgoinaSource :
- Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria [ 1115-2613 ]
Descripteurs français
- KwdFr :
- Afrique subsaharienne, Agents antiVIH (pharmacologie), Agents antiVIH (usage thérapeutique), Femelle, Génome, Humains, Infections à VIH (génétique), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mutation, Mâle, Pays en voie de développement, Polymorphisme génétique, Résistance virale aux médicaments (génétique), Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- génétique : Infections à VIH, Résistance virale aux médicaments, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Agents antiVIH.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- virologie : Infections à VIH.
- Afrique subsaharienne, Femelle, Génome, Humains, Mutation, Mâle, Pays en voie de développement, Polymorphisme génétique, Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Africa South of the Sahara, Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active, Developing Countries, Drug Resistance, Viral (genetics), Female, Genome, HIV Infections (drug therapy), HIV Infections (genetics), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), Humans, Male, Mutation, Polymorphism, Genetic.
- MESH :
- chemical , pharmacology : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- geographic : Africa South of the Sahara.
- drug effects : HIV-1.
- drug therapy : HIV Infections.
- genetics : Drug Resistance, Viral, HIV Infections, HIV-1.
- virology : HIV Infections.
- Antiretroviral Therapy, Highly Active, Developing Countries, Female, Genome, Humans, Male, Mutation, Polymorphism, Genetic.
Abstract
The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance.
PubMed: 21526620
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000072
Links to Exploration step
pubmed:21526620Curation
No country items
O R Obiako<affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation>
<wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.</title>
<author><name sortKey="Obiako, O R" sort="Obiako, O R" uniqKey="Obiako O" first="O R" last="Obiako">O R Obiako</name>
<affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation>
<wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Murktar, H M" sort="Murktar, H M" uniqKey="Murktar H" first="H M" last="Murktar">H M Murktar</name>
</author>
<author><name sortKey="Ogoina, D" sort="Ogoina, D" uniqKey="Ogoina D" first="D" last="Ogoina">D. Ogoina</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2010 Oct-Dec</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:21526620</idno>
<idno type="pmid">21526620</idno>
<idno type="wicri:Area/PubMed/Corpus">000072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000072</idno>
<idno type="wicri:Area/PubMed/Curation">000072</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000072</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.</title>
<author><name sortKey="Obiako, O R" sort="Obiako, O R" uniqKey="Obiako O" first="O R" last="Obiako">O R Obiako</name>
<affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation>
<wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Murktar, H M" sort="Murktar, H M" uniqKey="Murktar H" first="H M" last="Murktar">H M Murktar</name>
</author>
<author><name sortKey="Ogoina, D" sort="Ogoina, D" uniqKey="Ogoina D" first="D" last="Ogoina">D. Ogoina</name>
</author>
</analytic>
<series><title level="j">Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria</title>
<idno type="ISSN">1115-2613</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa South of the Sahara</term>
<term>Anti-HIV Agents (pharmacology)</term>
<term>Anti-HIV Agents (therapeutic use)</term>
<term>Antiretroviral Therapy, Highly Active</term>
<term>Developing Countries</term>
<term>Drug Resistance, Viral (genetics)</term>
<term>Female</term>
<term>Genome</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (genetics)</term>
<term>HIV Infections (virology)</term>
<term>HIV-1 (drug effects)</term>
<term>HIV-1 (genetics)</term>
<term>Humans</term>
<term>Male</term>
<term>Mutation</term>
<term>Polymorphism, Genetic</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne</term>
<term>Agents antiVIH (pharmacologie)</term>
<term>Agents antiVIH (usage thérapeutique)</term>
<term>Femelle</term>
<term>Génome</term>
<term>Humains</term>
<term>Infections à VIH (génétique)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Infections à VIH (virologie)</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Pays en voie de développement</term>
<term>Polymorphisme génétique</term>
<term>Résistance virale aux médicaments (génétique)</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa South of the Sahara</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Viral</term>
<term>HIV Infections</term>
<term>HIV-1</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Infections à VIH</term>
<term>Résistance virale aux médicaments</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term>
<term>Developing Countries</term>
<term>Female</term>
<term>Genome</term>
<term>Humans</term>
<term>Male</term>
<term>Mutation</term>
<term>Polymorphism, Genetic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Afrique subsaharienne</term>
<term>Femelle</term>
<term>Génome</term>
<term>Humains</term>
<term>Mutation</term>
<term>Mâle</term>
<term>Pays en voie de développement</term>
<term>Polymorphisme génétique</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21526620</PMID>
<DateCreated><Year>2011</Year>
<Month>04</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>09</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2011</Year>
<Month>04</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1115-2613</ISSN>
<JournalIssue CitedMedium="Print"><Volume>19</Volume>
<Issue>4</Issue>
<PubDate><MedlineDate>2010 Oct-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria</Title>
<ISOAbbreviation>Niger J Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.</ArticleTitle>
<Pagination><MedlinePgn>352-60</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The review was sourced from papers presented at international conferences on HIV/AIDS and rational drug use, relevant journals and Medline search using the keywords--Antiretroviral drugs, drug resistance, HIV subtypes and resistance testing.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The types, groups, subtypes, sub-subtypes and recombinant forms of HIV-1 have been identified according to their geographical distributions. The evolution of HIV viral mutations, process (es) involved in development of primary and secondary antiretroviral drug resistance, including the role of HIV genetic polymorphisms, and transmitted resistance have been discussed.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The pitfalls in the current resistance testing based on HIV-1 subtype B have been highlighted. The design of resistance testing algorithm based on HIV-1 subtype non-B has been suggested for the developing world.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obiako</LastName>
<ForeName>O R</ForeName>
<Initials>OR</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Murktar</LastName>
<ForeName>H M</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ogoina</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Nigeria</Country>
<MedlineTA>Niger J Med</MedlineTA>
<NlmUniqueID>100888321</NlmUniqueID>
<ISSNLinking>1115-2613</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017954" MajorTopicYN="N" Type="Geographic">Africa South of the Sahara</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003906" MajorTopicYN="N">Developing Countries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21526620</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000072 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000072 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= SidaSubSaharaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:21526620 |texte= Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21526620" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SidaSubSaharaV1
![]() | This area was generated with Dilib version V0.6.32. | ![]() |